
GLP-1 and DPP-4 inhibitors
Dipeptidyl peptidase 4 inhibitors, also DPP-4 inhibitors, are a new class of oral hypoglycemics. Their mechanism of action is thought to result from increased GLP-1,[1][2] which inhibits glucagon release (which increases the blood glucose).
Drugs belonging to this class are vildagliptin and sitagliptin.
References
- ^ Behme MT, Dupre J, McDonald TJ. Glucagon-like peptide 1 improved glycemic control in type 1 diabetes. BMC Endocr Disord. 2003 Apr 10;3(1):3. PMID 12697069. Full Free Text.
- ^ Dupre J, Behme MT, Hramiak IM, McFarlane P, Williamson MP, Zabel P, McDonald TJ. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes. 1995 Jun;44(6):626-30. PMID 7789625.
External links
- Vildagliptin - glucagon.com
- About DPP-4 - glucagon.com
- The race to get DPP-4 inhibitors to market - Forbes.com